Skip Navigation LinksHome > July 2014 - Volume 21 - Issue 7 > Health-related quality of life in women with or without hot...
doi: 10.1097/GME.0000000000000120
Original Articles

Health-related quality of life in women with or without hot flashes: a randomized placebo-controlled trial with hormone therapy

Savolainen-Peltonen, Hanna MD, PhD1,2; Hautamäki, Hanna MD1; Tuomikoski, Pauliina MD, PhD1; Ylikorkala, Olavi MD, PhD1; Mikkola, Tomi S. MD, PhD1,2

Collapse Box



We assessed the impact of hot flashes and various forms of hormone therapy on health-related quality of life and sexual well-being in recently postmenopausal women.


We prospectively interviewed 150 healthy women about hot flashes and health-related quality of life (using the Women’s Health Questionnaire and the McCoy Female Sexuality Questionnaire), menopause-related symptoms, and general health. The women were classified into those with (n = 72) and without (n = 78) hot flashes and treated for 6 months with transdermal estradiol (1 mg/d), oral estradiol (2 mg/d) with or without medroxyprogesterone acetate (5 mg/d), or placebo.


At baseline, hot flashes contributed most strongly to poor sleep (correlation coefficient r = −0.525, P < 0.0001), somatic symptoms such as muscle pains (r = −0.348, P < 0.0001), menstrual cycle–resembling complaints (r = −0.304, P < 0.0001), anxiety and fears (r = −0.283, P < 0.0001), decreased memory and concentration (r = −0.279, P = 0.001), and sexual behavior (r = −0.174, P = 0.035). The different hormone therapy regimens alleviated hot flashes equally effectively and were therefore combined into a single group for further analysis. In women with baseline flashes, hormone therapy use significantly improved the scores for sleep (0.787 [0.243] vs 0.557 [0.249], hormone therapy vs placebo, P = 0.001, at 6 mo), memory and concentration capacity (0.849 [0.228] vs 0.454 [0.301], P < 0.0001, at 6 mo), and anxiety and fears (0.942 [0.133] vs 0.826 [0.193], P = 0.005, at 6 mo). Hormone therapy use showed no significant impact on these variables in women without baseline flashes.


Hot flashes contribute differently to various variables affecting health-related quality of life shortly after menopause. Estradiol or an estradiol–medroxyprogesterone acetate combination similarly alleviates hot flashes and improves health-related quality of life in relation to elimination of hot flashes. Hormone therapy use does not confer any detectable quality-of-life benefit over placebo in women without disturbing baseline flashes.

© 2013 by The North American Menopause Society


Article Tools


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.